Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Arsene Bienvenu Loembe"'
Autor:
Pilar Garrido, Yvonne Summers, Ute von Wangenheim, Michael Flynn, Allan Hackshaw, Manuel Cobo, Siow Ming Lee, Anne-Marie C. Dingemans, Arsene Bienvenu Loembe, David Schnell, Rolf Kaiser, Martin Forster, Tommaso De Pas
Publikováno v:
Lung Cancer, 120, 27-33. Elsevier Ireland Ltd
Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line
Autor:
Tim Meyer, Daniel H. Palmer, Julia Hocke, Ann-Lii Cheng, Chia Jui Yen, Arsene Bienvenu Loembe
Publikováno v:
Liver International. 37:1047-1055
BACKGROUND & AIMS: Response Evaluation Criteria in Solid Tumors (RECIST) has been shown to be a poor surrogate for survival benefit with targeted therapy in advanced hepatocellular carcinoma (HCC). METHODS: We investigated whether response evaluated
Autor:
Shuichi Mitsunaga, Taiga Otsuka, Rie Sugimoto, Arsene-Bienvenu Loembe, Kei Muro, Masafumi Ikeda, Yusuke Tadayasu, Kohei Inoue, Isao Saito, Takuji Okusaka, Hideki Ueno
Publikováno v:
Cancer Science
This phase I, dose‐escalation study evaluated the safety, preliminary efficacy and pharmacokinetics of nintedanib, a triple angiokinase inhibitor, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment. Thirt
Autor:
Markus Peck-Radosavljevic, Arsene-Bienvenu Loembe, Yuk Ting Ma, Laetitia Fartoux, David Schnell, Janet Graham, Julia Hocke, Paul Ross, Daniel H. Palmer, Andrzej Deptała, Matus Studeny, Tim Meyer
Publikováno v:
British Journal of Cancer
Background: \ud This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7e888e571a39896fc792d7ffda6dbc
https://eprints.gla.ac.uk/159941/1/159941.pdf
https://eprints.gla.ac.uk/159941/1/159941.pdf
Autor:
David Planchard, Martin Reck, N. Morsli, Paul Taylor, Natasha B Leighl, José Barrueco, Federica Grosso, Silvia Novello, Sanjay Popat, Anna K. Nowak, Laurent Greillier, Giorgio V. Scagliotti, Thomas John, Mark A. Socinski, Nicola Steele, Jens Benn Sørensen, Arsene Bienvenu Loembe, Ute von Wangenheim
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3b67a7c511c65e68c6752a93e01b4b
http://hdl.handle.net/10044/1/55960
http://hdl.handle.net/10044/1/55960
Autor:
Julia Hocke, Deng Yn Lin, Yin Hsun Feng, Dennis Chin-Lun Huang, Baek Yeol Ryoo, Ann-Lii Cheng, Yee Chao, Chia Jui Yen, Tae-You Kim, Arsene Bienvenu Loembe, David Schnell
Publikováno v:
Liver cancer. 7(2)
Background: Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor receptors. This randomized, multicenter, open-label, phase I/II study evaluated the safety,
Autor:
David Planchard, Jens Benn Sørensen, Mark A. Socinski, Federica Grosso, Nicola Steele, Martin Reck, Anna K. Nowak, Arsene Bienvenu Loembe, Paul J. Taylor, Nick Pavlakis, Sanjay Popat, Ute von Wangenheim, José Barrueco, Giovanni Luca Ceresoli, Natasha B. Leighl, Julien Mazieres, Thomas John, Laurent Greillier, N. Morsli, Silvia Novello, Martha Mueller, Giorgio V. Scagliotti, Brett G.M. Hughes
Publikováno v:
Journal of Thoracic Oncology. 12:S329-S330
Autor:
Timothy Eisen, Robert Jones, Graham Temple, Yaroslav Shparyk, N. MacLeod, Arsene-Bienvenu Loembe, Igor Bondarenko, Mazurkiewicz M, Dressler H
Publikováno v:
British Journal of Cancer
background: This exploratory study evaluated the safety/efficacy of nintedanib or sunitinib as first-line therapy in patients with advanced renal cell carcinoma (RCC).\ud methods: Ninety-six patients were randomised (2:1) to either nintedanib (200 mg
Autor:
Marc Peeters, Timothy Iveson, Niall C. Tebbutt, Taroh Satoh, Takayuki Yoshino, Mark Harrison, Arsene-Bienvenu Loembe, Christian Dittrich, Eric Van Cutsem, Heinz-Josef Lenz, Howard John Lim, Mouna Sassi, Javier Sastre, Guillem Argiles
Publikováno v:
Journal of Clinical Oncology. 35:660-660
660 Background: N is a triple angiokinase inhibitor (including VEGFR, PDGFR and FGFR). LUME-Colon 1 (NCT02149108) evaluated the efficacy and safety of N in pts with metastatic CRC (mCRC) after failure of standard therapies and showed a statistically
Autor:
Tim Eisen, Igor Bondarenko, Arsene-Bienvenu Loembe, Claudia Dallinger, Yaroslav Shparyk, Robert Jones, Matus Studeny, Yasser Khder, Graham Temple, Gudrun Wallenstein, N. MacLeod
Publikováno v:
Investigational new drugs. 31(5)
Purpose Some targeted anticancer agents are associated with serious ventricular tachyarrhythmias, which may be predicted by electrocardiographic evaluation of drug-related QT prolongation. We studied the effects of nintedanib (BIBF 1120; an oral, tri